Showing 1 - 10 of 11
innovation, we characterize such "radical teams" as those formed by eclectic and non-usual collaborators, and those that are …
Persistent link: https://www.econbiz.de/10011451136
Pharmaceutical firms spend increasing amounts in mergers and acquisitions (M&As), which raises the question of whether sufficient investment is left after mergers to further develop firms' internal drug development capability. We evaluate the effects of M&As on firms' post-merger R&D...
Persistent link: https://www.econbiz.de/10012219372
This paper evaluates how different lengths of entry regulation impact market structure and market performance using a dynamic structural model. We formulate an oligopoly model in the tradition of Ericson and Pakes (1995) and allow entry costs to vary over time. Firms have the opportunity to...
Persistent link: https://www.econbiz.de/10009764443
In the last decades, technologies became more complex which increased the degree of uncertainty in R&D. To overcome the uncertainty, firms frequently engage in R&D collaborations, e.g., Research Joint Ventures (RJVs), and licensing agreements. While RJVs are well explored in the literature, very...
Persistent link: https://www.econbiz.de/10010223406
We study innovation contests with asymmetric information and identical contestants, where contestants' efforts and … highest quality and receives the revenue generated by the innovation. We characterize the equilibrium behavior, outcomes and …
Persistent link: https://www.econbiz.de/10010260048
We study the effect of analyst coverage on firms' innovation strategy and outcome. By considering three different … negative effect becomes not significant when firms' in-house R&D spending and external innovation channels are taken into … account. We find that more financial analysts encourage firms to make more efficient investments related to innovation, which …
Persistent link: https://www.econbiz.de/10011688059
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
We provide a theoretical framework to contribute to the current debate regarding the tendency of pharmaceutical companies to direct their R&D toward marketing products that are "follow-on" drugs of already existing drugs, rather than toward the development of breakthrough drugs. We construct a...
Persistent link: https://www.econbiz.de/10011406575
We develop a two-sided matching model to analyze collaboration between heterogeneous academics and firms. We predict a positive assortative matching in terms of both scientific ability and affinity for type of research, but negative assortative in terms of ability on one side and affinity in the...
Persistent link: https://www.econbiz.de/10009772922
-level information on mergers, production, and innovation in the dynamic random access memory semiconductor market from 1985 to 2004. Our …
Persistent link: https://www.econbiz.de/10011481190